… vaccines that offer more effective and broad-spectrum protection. Here, we report a circular
RNA (circRNA) vaccine … , providing robust protection against SARS-CoV-2 in both mice and …

… responses to messenger RNA SARS-CoV-2 vaccines? … after the second messenger RNA
BNT162b2 vaccine dose.. … to messenger RNA SARS-CoV-2 vaccines and that vaccination of …

… We examined antibody response after the first and second doses of vaccines in the subset
of patients with prior SARS-CoV-2 infection who were excluded from the overall vaccine …

… Francophone Society of Transplantation, anti–SARS-CoV-2 spike protein antibodies were
monitored before and after vaccination. We used the SARS-CoV-2 total antibodies enzyme-…

… that have received conditional marketing authorization are inactivated virus vaccines, RNA
vaccines, and viral vector vaccines. For this reason, this article will make a systematic review …

… RNA replicons were formulated with lipid inorganic nanoparticles (LIONs) that were
designed to enhance vaccine … -CoV2S vaccine in mice elicited robust production of anti–SARS-CoV-…

… RNA vaccine exist against infectious pathogens, or non-replicating mRNA vaccine and
self-amplifying or replicon RNA vaccine … , non-replicating mRNA vaccines are further divided as …

… SARS-CoV-2 mRNA vaccination. Results range from <0.4 to >250 U/mL with positive antibody
defined as an anti-SARS-CoV-… two-dose SARS-CoV-2 mRNA vaccination in patients with …

Objective To evaluate disease flare and postvaccination reactions (reactogenicity) in
patients with rheumatic and musculoskeletal diseases (RMDs) following 2‐dose SARS–CoV‐2 …

… US adult HT and LT recipients completed their vaccine series between January 7 and April
10, 2021. Reactogencity and SARS-CoV-2 anti-spike antibody were assessed after a priming …